GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.
While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...
Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...
Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...
Takeda Pharmaceuticals’ dengue vaccine, Qdenga, has demonstrated long-term efficacy in preventing infections and hospitalisations in a seven-year Phase III study. Image credit: SILVIA MAQQ via ...
Kelun-Biotech’s Sac-TMT has met its primary endpoint of PFS improvements in combination with MSD’s Keytruda in comparison to the checkpoint inhibitor alone in a Phase III trial. Image credit: Butusova ...
Novartis’ RLT received US FDA approval for earlier use in mCRPC. Credit: Konektus Photo/Shutterstock. Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified ...
Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.
Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...
In 2018, roughly a year before the World Health Organization declared Covid-19 a global health emergency, a conference in Edinburgh imagined a very different type of medical crisis: during a ...
The never-ending challenge of finding and recruiting eligible clinical trial participants continues to push sponsors to find new avenues to expedite enrolment. As decentralisation shakes up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback